trastuzumab
Not Tagged
['trastuzumab', '#gi', 'gi ']
#asco22 #asco2022 #gioncology #meded gi oral abstract #5: use of trastuzumab-deruxtecan in her2+ biliary tract cancers: background: gem/cis is approved for first line and multiple targeted therapies have been identified, eg against idh2, fgfr, etc.
Stanford Oncologist || BYU alum || Penn Med alum || author || American Studies amateur || religious studies amateur || podcasting @ https://t.co/KnVbI8oZ43